Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 30,000 shares, a drop of 36.8% from the November 15th total of 47,500 shares. Based on an average daily trading volume, of 42,400 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.9% of the shares of the stock are sold short.

Institutional Investors Weigh In On Lakeshore Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of LSB. FMR LLC acquired a new stake in shares of Lakeshore Biopharma during the third quarter valued at about $803,000. Hhlr Advisors LTD. bought a new stake in Lakeshore Biopharma during the 3rd quarter worth approximately $513,000. Finally, Barclays PLC acquired a new position in Lakeshore Biopharma in the 3rd quarter valued at approximately $169,000. Institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Stock Performance

Shares of NASDAQ LSB traded down $0.04 during midday trading on Friday, reaching $2.50. 4,609 shares of the company were exchanged, compared to its average volume of 14,336. The company’s 50-day moving average price is $2.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.87 and a current ratio of 1.13. Lakeshore Biopharma has a one year low of $1.88 and a one year high of $11.20.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.